MedAdvisor Continues Growth of Tap To Refill Feature

12th October 2016, ASX Announcement

• Tap to Refill function continues to gain traction, reaching over 2 million script orders for the first time since inception in Q1, CY 2014
• Annualised script value now passing through the platform is over $75 million, signalling strong engagement with the function of ~40% of  MedAdvisor’s patients
• Upon completion of Healthnotes acquisition the total of annualised value of script orders is expected to reach more than $160 million
• Ongoing growth of the service represents the real value and convenience the function delivers to patients, providing further validation of its demand and importance for patients
• Further Patient Engagement Programs (PEPs) for additional products signed during October, delivering further PEP revenue in the December quarter

MedAdvisor Limited (ASX: MDR, the Company), Australia’s leading digital medication adherence company are pleased to provide an update on its innovative Tap to Refill function.

For the first time since the function was launched in Q1, CY 2014, it has now processed over 2 million scripts. On an annualised basis, this amounts to over $75 million of script value being ordered through the platform. This is an increase of 118% on the same quarter last year, and represents the growing use and engagement of the MedAdvisor platform.

To view the full announcement, please click on the button below.